Transition Probabilities and Predictors of Adherence in a California Medicaid Population Using Antihypertensive and Lipid-Lowering Medications  by Nichol, Michael B. et al.
Transition Probabilities and Predictors of Adherence in a
California Medicaid Population Using Antihypertensive and
Lipid-Lowering Medications
Michael B. Nichol, PhD,1 Tara K. Knight, PhD,1 Joanne Wu, MS,1 Simon S. K. Tang, MPH,2 Spencer B. Cherry, BA,3
Joshua S. Benner, PharmD, ScD,3 Mohamed Hussein, PhD3
1Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los
Angeles, CA, USA; 2Global Outcomes Research, Pﬁzer, Inc., New York, NY, USA; 3IMS Consulting, Inc., Falls Church,VA, USAvhe_474 544..550
ABSTRACT
Objectives: To determine adherence rates, transition probabilities, and
factors associated with transition from higher to lower adherence in anti-
hypertensive (AH) and lipid-lowering (LL) medications.
Methods: California Medicaid data (1995–2003) were used to identify
hypertensive patients with prescriptions for both AH and LL medications.
Proportion of days covered (PDC) was used to deﬁne three adherence
classiﬁcations: fully adherent (FA, PDC  0.8), partially adherent (PA,
0.2  PDC < 0.8), and nonadherent (NA, PDC < 0.2). Annual transition
matrices documented the probability of adherence status changes.
Results: Only 13% of the 5943 patients were FA to both drugs at baseline.
Patients who were FA (60%) or NA (84%) to both drugs had high
probability of maintaining status at year two (Y2). Signiﬁcant variables
associated with a transition from adherent to NA at Y2 included African
American race (odds ratio [OR] 1.5), other race groups (OR 1.2), lack of
Medicare eligibility (OR 1.3), and initiating LL therapy of ﬁbric acid
derivatives (OR 1.3) or niacin (OR 1.8).
Conclusions: Patients FA or NA with both drugs at baseline were more
likely to maintain their adherence status. Race, insurance coverage, and
type of LL medication were signiﬁcantly associated with transitioning
from any adherence status to nonadherence. These ﬁndings may be
useful in guiding cost-effectiveness analyses incorporating adherence
estimates.
Keywords: adherence, antihypertensive medications, California Medicaid,
lipid-lowering medications, transition probabilities.
Introduction
Cardiovascular disease (CVD) is one of the leading causes of
death in the United States. The estimated direct and indirect
ﬁnancial costs related to CVD reached $431.8 billion in the
United States in 2005 [1]. Both hypertension and dyslipidemia
are strongly associated with CVD, and patients with a comorbid
diagnosis of the two diseases are at an increased risk for coronary
heart disease events [2]. A current systemic literature review
revealed that lipid management provides clinical beneﬁt in
patients at high risk of CVD, and that lipid-lowering (LL) with
statin therapy provides additional beneﬁts over antihypertensive
(AH) therapy alone in high-risk patients with hypertension [3].
The Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-
Lowering Arm [4] recently demonstrated that combination
treatment with amlodipine and atorvastatin in patients with
uncontrolled hypertension, multiple cardiovascular risk factors,
and normal cholesterol levels reduced the risk of cardiovascular
events compared to patients treated with amlodipine and
placebo. The National Cholesterol Education Program Adult
Treatment Panel III guidelines [5] recommend that for patients at
high risk for CVD, LL therapy should be considered even at
relatively low cholesterol levels.
Despite demonstrated effectiveness in controlling blood pres-
sure and lipid proﬁle [3–8], long-term adherence and persistence
with prescribed drug therapy remains a common problem for
both LL and AH drugs [9–13]. There is still much to be deter-
mined about adherence with concomitant AH and LL therapy, as
most studies have focused on compliance within a single drug
class only. One study retrospectively investigating a managed
care population treated with AH and LL therapy found that only
one in three patients were adherent with both medications at 6
months [14]. There has been limited research assessing longitu-
dinal change in adherence status with multiple-drug regimens.
Caspard and colleagues [15] investigated compliance with statins
in an HMO population over a 3-year time period. They found
that the risk of discontinuation was high during the ﬁrst 6
months of therapy, with 20% discontinuation during that time.
Discontinuation tapered off over subsequent years with 74%,
65%, and 61% remaining on treatment at years 1, 2, and 3,
respectively.
Health-care claims data do not reveal the reasons for termi-
nation of therapy but can be helpful in identifying issues of
nonadherence with medications used to treat chronic disease.
Claims data have successfully provided a valuable source of
information with some degree of predictive ability, especially
when compared to other adherence monitoring methods [16,17].
Pladevall and colleagues [18] found that claims-based measures
of adherence were linked to outcomes in diabetic patients.
Understanding both the magnitude of adherence with con-
comitant use of AH and LL as well as adherence over time
are critical when evaluating outcomes and implementing cost-
effectiveness analyses. Adherence with AH and LL medications is
an important determinant for successful management of hyper-
tension and dyslipidemia, and may also impact the economics of
disease management. Therefore, the transition probabilities of
adherence status in combination use of AH and LL are an inte-
gral part of pharmacoeconomic evaluation and health-care
decision-making. Nevertheless, research in this area is sparse
[19]. The objectives of the current study included: 1) determining
adherence rates and transition probabilities of adherence status
(fully adherent [FA], partially adherent [PA], and nonadherent
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[NA]) over time; and 2) identifying the factors associated with
transition from higher adherence to lower adherence for a popu-
lation with combination use of AH and LL medications.
Materials and Methods
Data Source and Study Population
This study is based on a publicly available 20% sample of Cali-
fornia Medicaid (Medi-Cal) fee-for-service claims data from
January 1995 through December 2003. The Institutional Review
Board of the principal investigator’s institution and the Califor-
nia Health and Human Services Agency’s Committee for Protec-
tion of Human Subjects both reviewed and approved the study
protocol.
Medi-Cal administrative data captured a computerized data-
base of linked eligibility, pharmacy, and physician/medical claims
data. The eligibility data contained information on eligibility
within the Medi-Cal program as well as social demographic data.
The Medi-Cal crossover system included data for patients who
were dually (Medicaid/Medicare) eligible. The pharmacy and
physician claims data included speciﬁc drug dispensed (National
drug codes [NDC]), quantity dispensed, number of days’ supply,
service dates, and disease diagnoses based on codes from the
International Classiﬁcation of Diseases, Ninth Revision (ICD-9).
Patients were included in the analyses if they met all of the
following criteria: 1) 40 years of age or older on the date of the
ﬁrst prescription ﬁll on record for either an LL or AH medica-
tion; 2) a primary or secondary diagnosis of hypertension (ICD-9
codes 401.x to 404.x) on any claim; and 3) a prescription for
both an LL and AH medication within 180 days of each other.
We deﬁned the index date as the ﬁrst prescription ﬁll for an LL or
AH, whichever occurred later on record to ensure that medica-
tions have the same starting point to calculate compliance. For
example, if a prescription ﬁll for an LL was the ﬁrst prescription
on record, an AH prescription must also have occurred within
180 days of the ﬁrst LL prescription. In this case, the ﬁrst AH was
labeled as the index prescription. Finally, patients were required
to have continuous eligibility, 6 months before the ﬁrst AH or LL
prescription and at least 24 months after the index prescription
to allow for an adequate observation period. Patients were
excluded from the analysis if they had a diagnosis for coronary
heart disease, stroke, or diabetes in the 6 months before the index
date.
LL and AH Drugs
NDCs from the claims data were merged with the hierarchical
ingredient code-speciﬁc therapeutic classiﬁcation system from the
National Drug Data File (NDDF) Plus (First Data Bank, Inc.).
The medication classes for LL drugs that were identiﬁed from
NDDF are used only for LL. Therefore, evidence of a prescrip-
tion ﬁll for an LL medication served as a proxy for a diagnosis of
dyslipidemia. Patients who were prescribed one of three classes
of drugs (3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors [statins], ﬁbric acid derivatives, and niacin) were iden-
tiﬁed as receiving treatment with LL drugs. Patients receiving
sympatholytic, angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor antagonist, ACE inhibitor and calcium
channel blocker combination, calcium channel blockers, alpha-
adrenergic blockers, beta-adrenergic blockers, alpha and beta-
adrenergic blocker combination, and thiazide and related
diuretics were identiﬁed as receiving treatment with AH drugs.
We did not include patients who used ﬁxed-dose combination
AH and LL so that we were able to calculate AH and LL
compliance separately.
Adherence
A proportion of days covered (PDC) was applied to this study as
a measure of adherence. The PDC was calculated as the number
of days with any AH or LL drug on hand divided by the number
of days in the speciﬁed time interval (360 days) [20]. A uniform
period of 1 year (360 days) was used in our calculation to ensure
equal and accurate long-term adherence behavior proﬁles [21].
Adherence was calculated for AH and LL separately. The PDC
calculation was used to deﬁne three adherence classiﬁcations: FA
(PDC  0.8), PA (0.2  PDC < 0.8), and NA (PDC < 0.2) [12].
Adherence Rate and Transition Probability
Annual adherence rates on combination use of LL and AH were
calculated for year one (Y1) through year six (Y6), depending on
the length of time a given patient was continuously eligible
following the index prescription. A total of nine combinations of
adherence were created, corresponding to the possible combina-
tion of LL and AH adherence status. Transition probabilities
were calculated based on the adherence rate from a previous
status to a new status for patients with complete data for both
the starting and ending year (e.g., the transition probability of
year (i) from status A to status B = incidence of status B during
year (i)/the number of patients in status A in year (i–1) (Fig. 1).
Annual transition matrices documented the probability of adher-
ence status changes for Y1 to Y6.
Statistical Analyses
The descriptive statistics for combination usage in LL and AH
were calculated. Univariate chi-square analyses were used to
compare sociodemographic factors, dually eligible status, and LL
and AH drug use between patients who transitioned from any
adherence to nonadherence status from Y1 to year two (Y2) and
those who did not transition to NA status. As patients were lost
to follow-up beyond Y2, only Y1 to Y2 transitions are empha-
sized in this article. Logistic regression models were used to
assess the factors associated with the transition from any adher-
ence status to lower adherence or fully NA status. Statistical
signiﬁcance was deﬁned at the <0.05 level. All analyses were
conducted using SAS software (Version 9.1, SAS Institute, Inc.,
Cary, NC).
Results
Description of Study Population
Within the study period, 107,961 Medi-Cal enrollees were
potentially eligible, as they had at least one diagnosis for hyper-
tension and prescriptions for both LL and AH medications.
Based on the inclusion criteria, a total of 5943 (5.5%) patients
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Figure 1 Transition probability calculation formula.
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were identiﬁed. Patient demographics, eligibility, and index drug
use are presented in Table 1. Mean age was 64.2 years (SD 11.1
years), with approximately 55% of the population 65 years of
age or older. Sixty percent were female, 38% were Caucasian,
and 72% were eligible for both Medi-Cal and Medicare. No
signiﬁcant differences were found between patients who transi-
tioned to and those who did not transition to nonadherence
from Y1 to Y2 for age, sex, or AH drug use. Chi-square tests
revealed that relative to patients who did not transition to non-
adherence, those who did transition to nonadherence from Y1 to
Y2 were more likely to be African American or other race
(although a greater proportion of the sample were Caucasian or
other race groups within each adherence cohort), to be dually
eligible, and to have no evidence of statin utilization as the LL
treatment.
Proportion of Patients at Various Stages of Adherence to
Combination Use of LL and AH Drugs
Of the 5943 patients who were in the study in Y1, 1861 (31.3%)
were PA to both AH and LL, 1092 (18.4%) were FA to AH and
PA to LL, 755 (12.7%) were FA to both drugs, 657 (11.1%) were
PA to AH and NA to LL, and 528 (8.9%) were NA to both
drugs. The adherence rates for other possible combinations were
7% or less in Y1 (Table 2). Of the 1477 patients who remained
in the analysis at Y6, 576 (39%) were NA to both drugs, 297
(20.1%) were FA to both drugs, 188 (12.7%) were PA to both
drugs, and 182 (12.3%) were FA to AH and PA to LL. All other
possible combinations of adherence status were 4.3% or less
(Table 2). For FA or NA status to both drugs, the adherence rates
increased from Y1 to Y6. Nevertheless, adherence rates for
Table 1 Patient demographic, eligibility, and index drug use by adherence transition status from year one to year two
Total N = 5943
Transition to nonadherence with both
AH and LL from year 1 to year 2
P-value*No N = 4314 Yes N = 1629
Age 0.49
<65 years 2657 (44.7) 1917 (44.4) 740 (45.4)
65+ years 3286 (55.3) 2397 (55.6) 889 (54.6)
Sex 0.15
Female 3577 (60.2) 2621 (60.8) 956 (58.7)
Male 2366 (39.8) 1693 (39.2) 673 (41.3)
Race 0.001
Other 3279 (55.2) 2358 (54.7) 921 (56.5)
Caucasian 2226 (37.5) 1666 (38.6) 560 (34.4)
African American 438 (7.4) 290 (6.7) 148 (9.1)
Insurance coverage 0.0002
Medi-Cal only 1668 (28.1) 1154 (26.8) 514 (31.6)
Medi-Cal and Medicare† 4275 (71.9) 3160 (73.2) 1115 (68.4)
Index lipid-lowering drug class 0.01
Statins 5413 (91.1) 3957 (91.7) 1456 (89.4)
Fibric acid derivatives 470 (7.9) 320 (7.4) 150 (9.2)
Niacin 60 (1.0) 37 (0.9) 23 (1.4)
Index antihypertensive drug class 0.38
Alpha blockers 322 (5.4) 222 (5.1) 100 (6.1)
ACE inhibitors 1797 (30.2) 1317 (30.5) 480 (29.5)
Angiotensin receptor antagonist 417 (7.0) 289 (6.7) 128 (7.9)
Beta blockers 1009 (17.0) 736 (17.1) 273 (16.8)
Calcium channel blockers 1887 (31.8) 1368 (31.7) 519 (31.9)
Diuretics 328 (5.5) 242 (5.6) 86 (5.3)
Others 183 (3.1) 140 (3.2) 43 (2.6)
*p < 0.05.
†Patients were eligible for both California Medicaid and Medicare during year one.
Data are presented as frequencies (percentages) based on column total. P-values were calculated using chi-square tests.
AH, antihypertensive medication;ACE, angiotensin-converting enzyme; LL, lipid-lowering medication.
Table 2 Annual adherence rates for combination use of antihypertensive and lipid-lowering drugs from year one to year six in a hypertensive Medi-Cal
population
Adherence status Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
FF 12.7 18.5 17.6 19.2 21.1 20.1
FP 18.4 11.5 11.1 10.8 12.3 12.3
FN 2.5 1.9 2.2 2.3 2.7 2.8
PF 7.0 4.2 4.1 3.5 4.0 3.3
PP 31.3 16.1 13.3 12.8 10.9 12.7
PN 11.1 4.4 4.1 3.3 3.1 3.1
NF 1.1 2.5 2.7 2.7 2.5 2.5
NP 7.0 6.1 5.7 4.6 4.4 4.3
NN 8.9 34.9 39.3 40.8 39.0 39.0
Sample size 5943 5943 4369 3301 2378 1477
Adherence rates are presented as percentages. Adherence statuses are presented as antihypertensive (AH)/lipid-lowering (LL) adherence. F, fully adherent; N, nonadherent; P, partially
adherent. For example, FF represents fully adherent to both AH and LL; FP represents fully adherent to AH, partially adherent to LL; FN represents fully adherent to AH, and nonadherent to
LL.
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partial adherence to both drugs decreased from Y1 to Y6. The
combination drugs in order of most to least frequently used
include: statins with calcium blockers (29%), statins with ACE
inhibitor (27%), and statins with beta blocker (15%). Other
combination drugs were used, 6% or less for each combination.
Annual Transition Probability for Adherence Status
Tables 3 and 4 display the annual transition probabilities for
adherence status for Y1 to Y2 and Y5 to Y6, respectively. Patients
who were FA to both drugs at Y1 had a 60% probability of
maintaining the status at Y2. Those who were PA to both AH and
LL had a 26% probability to maintain the status at Y2. Patients
who were FA to AH and PA to LL had a 30% probability to
transition to FA for both drugs, while those PA to AH and FA to
LL had a 33% probability of transitioning to FA. Patients who
were NA to LL but adherent to AH had higher probabilities of
transitioning to the nonadherence category for both drugs (AH:
59% FA, 71% PA) than those patients NA to AH but adherent to
LL (LL: 3% FA, 48% PA) (P < 0.0001). Patients who were FA or
PA to LL had more than a 22% (range from 22% [NA to AH] to
60% [FA to AH]) probability to maintain the status in Y2. Those
patients NA to both drugs in the ﬁrst year had an 84%probability
for maintaining NA status. These results are similar for each year
within the 6-year period. Nevertheless, patients had a higher
probability of maintaining the same adherence status between
years ﬁve and six than between years one and two.
Predictors of Transition from Higher Adherence to
Lower Adherence
Logistic regression results show that African American race
(odds ratio [OR] 1.28; 95% conﬁdence interval [CI] 1.05–1.58)
and Medi-Cal only coverage (OR 1.23; 95% CI 1.07–1.40) were
signiﬁcantly associated with a transition from higher (FA to both
drugs or at least PA with one drug) to lower adherence status
from Y1 to Y2 (Table 5). The variables that were signiﬁcantly
associated with a transition from a higher adherence status to
NA for both drugs at Y2 include other race (OR 1.15; 95% CI
1.02–1.31), African American race (OR 1.51; 95% CI 1.21–
1.88), Medi-Cal only coverage (OR 1.34; 95% CI 1.15–1.55),
and initiating LL therapy with ﬁbric acid derivatives (OR 1.26;
95% CI 1.02–1.54) or niacin (OR 1.72; 95% CI 1.02–2.91)
(Table 5).
Discussion
In the current analysis, we found that proportion of patients
achieving adherence for both combination use of AH and LL
medication was extremely low, with only 13% FA and 31% PA
to both drugs in the ﬁrst year following medication initiation.
The percentage of patients FA to both drugs increased slightly
from Y2 to Y6. The percentage of patients who were NA to both
drugs increased sharply from 8.9% at Y1 to 35%, 41%, and
39% at years two, four, and six, respectively. The increase in
percentage of FA patients in the follow-up years may be
explained by the transition from PA to one drug but FA to
another, to FA for both drugs (66% total probability). The per-
centage of patients FA to both medications in the current study is
lower than ﬁndings from a previous study [14] conducted within
a US managed care population. This ﬁnding may be due to the
Medicaid population in our study having greater issues with
treatment adherence due to lack of access to care or other
resources.
Table 3 Transition probability metrics for combination use of lipid-lowering and antihypertensive drugs from year one to year two (N = 5943)
Year 1
adherence
status
Year 2 adherence status
FF
(N = 1100)
FP
(N = 684)
FN
(N = 114)
PF
(N = 247)
PP
(N = 957)
PN
(N = 259)
NF
(N = 146)
NP
(N = 361)
NN
(N = 2075)
FF (N = 755) 59.9 15.0 1.5 7.7 11.5 0.5 0.8 0.7 2.5
FP (N = 1092) 30.0 25.5 4.0 4.0 14.2 3.5 0.4 0.6 17.7
FN (N = 148) 2.0 16.2 12.8 0 5.4 4.7 0 0 58.8
PF (N = 418) 33.0 12.0 0.7 14.6 16.7 2.4 8.6 6.7 5.3
PP (N = 1861) 8.8 9.9 1.4 3.2 26.3 6.4 1.6 7.8 34.7
PN (N = 657) 1.1 3.8 1.4 0.2 11.3 7.2 0.5 4.1 70.6
NF (N = 68) 1.5 2.9 0 13.2 7.4 2.9 35.3 33.8 2.9
NP (N = 416) 1.2 1.4 0.2 3.4 10.8 4.3 9.6 21.9 47.1
NN (N = 528) 0.6 0.2 0.2 0.2 4.5 2.7 0.6 6.6 84.5
Transition probabilities are presented as percentages. Adherence statuses are presented as antihypertensive (AH)/lipid-lowering (LL) adherence. F, fully adherent; N, nonadherent; P, partially
adherent. For example, FF represents fully adherent to both AH and LL; FP represents fully adherent to AH, partially adherent to LL; FN represents fully adherent to AH, and nonadherent to
LL.
Table 4 Transition probability metrics for combination use of antihypertensive and lipid-lowering drugs from year ﬁve to year six
Year 5
adherence
status
Year 6 adherence status
FF (N = 297) FP (N = 182) FN (N = 41) PF (N = 48) PP (N = 188) PN (N = 45) NF (N = 37) NP (N = 63) NN (N = 576)
FF (N = 302) 64.9 15.2 1.7 7.3 8.6 1.0 0 0.3 1.0
FP (N = 171) 29.2 38.0 4.1 2.3 11.1 3.5 0 0.6 11.1
FN (N = 42) 9.5 28.6 19.0 2.4 0 2.4 0 0 38.1
PF (N = 55) 45.5 10.9 1.8 16.4 16.4 1.8 1.8 3.6 1.8
PP (N = 159) 9.4 12.6 1.3 3.8 45.9 5.7 2.5 5.0 13.8
PN (N = 41) 2.4 4.9 0 2.4 31.7 22.0 2.4 0 34.1
NF (N = 45) 4.4 0 0 4.4 13.3 0 53.3 20.0 4.4
NP (N = 60) 1.7 0 1.7 3.3 21.7 5.0 10.0 35.0 21.7
NN (N = 606) 0.5 5.1 2.8 0.2 4.8 2.2 0.2 3.5 80.7
Transition probabilities are presented as percentages. Adherence statuses are presented as antihypertensive (AH)/lipid-lowering (LL) adherence. F, fully adherent; N, nonadherent; P, partially
adherent. For example, FF represents fully adherent to both AH and LL; FP represents fully adherent to AH, partially adherent to LL; FN represents fully adherent to AH, and nonadherent to
LL.
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This study assessed both the transition probabilities of longi-
tudinal adherence status and the risk factors inﬂuencing the
probabilities of transitioning from high to low adherence status
for combination use of AH and LL. Although a few investigators
have explored the long-term persistence in use of statins or AH
[12], few studies have documented the adherence rate and the
transition probabilities for combination use of AH and LL. The
data from our Medi-Cal hypertensive population indicated that
patients who were NA to LL but adherent to AH had higher
probabilities of transitioning to NA status in both drugs as
compared to those who were NA to AH but adherent to LL.
Patients who were either FA or NA to both drugs in the ﬁrst year
had high probabilities (FA: 60%, NA: 84%) for maintaining the
same adherence status in the subsequent 5-year period. Identiﬁ-
cation of the factors that are associated with nonadherence to
both drugs at the time of treatment initiation, as well as the
barriers to treatment adherence, may provide some insight in
targeting adherence interventions.
The second purpose of the study was to investigate the
factors associated with transition from higher adherence to
lower adherence in combination use of AH and LL medications.
One of the most important variables associated with the tran-
sition to nonadherence in both medication classes was the
choice of LL drugs, including the absence of treatment with
statins, use of niacin (OR 1.72), and use of ﬁbric acid deriva-
tives (OR 1.26). This ﬁnding corroborates previous literature
suggesting a higher rate of discontinuation, especially in non-
statin LL drugs [22]. This ﬁnding may be related to medication
side effects, as 80% of patients treated with niacin experience
ﬂushing, itching, and tingling of the face, which can impact
adherence [22,23].
Race was identiﬁed as one important factor impacting the
transition to NA status. African American race (OR 1.51) and
other race groups (OR 1.15) were more likely to transition to
NA status in the follow-up year as compared to Caucasians. As
previous studies have suggested that deaths from heart disease
are higher in African Americans than in Caucasians [24], these
ﬁndings are especially noteworthy. In general, minority popula-
tions are disproportionately underserved in health care [25],
which may mean that they are not getting the appropriate
knowledge, medical attention, and support to remain on their
medication. Future research should be conducted to determine
whether racial disparities in response to LL and AH medications
exist and whether this may explain the differences in discon-
tinuation rates. Finally, we discovered that patients with Medi-
Cal only insurance coverage (28%) were more likely to
transition to lower adherence or NA status when compared to
those with both Medicare and Medi-Cal insurance coverage
(OR 1.23, 1.34, respectively). Insurance coverage is known to
increase access to care, as well as to improve health outcomes
[26,27]. Level of drug coverage can have an impact on medi-
cation reﬁlling behavior [28]. Thus, increasing Medicare eligi-
bility may improve patient adherence in combination use of AH
and LL.
Limitations
Our analyses were subject to several limitations. First, Medi-Cal
claims data do not include clinical measures, which limited us in
the estimation of disease severity and clinical outcome. We were
unable to assess whether disease severity and treatment outcomes
were associated with adherence status and transition probabili-
ties. Some studies have shown that claims data in adherence have
been associated with clinical outcomes [18]. Nevertheless, as the
objectives in the current study did not include the evaluation of
clinical outcome, lack of clinicalmeasures do not impact our study
outcome. Second, lost eligibility translates into lack of patient
follow-up data, which consequently has an impact on analysis
power. We performed an additional analysis to include patients
who had 6 years of continuous eligibility following the index date
(data tables available from author by request). We compared the
results from this analysis with the original cohort of patients with
only 24 months eligibility. We found that the patterns for compli-
ance rates and transition probabilities were similar across cohorts,
Table 5 Logistic regression predicting transition from any adherence status to lower adherence status from year one to year two (N = 5943)
Variables
Transition to lower adherence
from year 1 to year 2
Transition to nonadherence
from year 1 to year 2
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Age 0.14 0.14
<65 years 1.00 1.00
65 years 1.10 (0.97, 1.24) 1.11 (0.97, 1.28)
Sex 0.14 0.21
Male 1.00 1.00
Female 0.92 (0.83, 1.03) 0.93 (0.83, 1.04)
Race 0.05 0.007
Caucasian 1.00 1.00
Other 1.07 (0.96, 1.20) 1.15 (1.02, 1.31)
African American 1.28 (1.05, 1.58) 1.51 (1.21, 1.88)
Insurance coverage 0.003 0.001
Medi-Cal and Medicare* 1.00 1.00
Medi-Cal only 1.23 (1.07, 1.40) 1.34 (1.15, 1.55)
Index LL class 0.26 0.01
Statins 1.00 1.00
Niacin 1.31 (0.79, 2.19) 1.72 (1.02, 2.91)
Fibric acid derivatives 1.13 (0.94, 1.37) 1.26 (1.02, 1.54)
Index AH class 1.00 0.31 0.72
Other 1.00 1.00
CCB 0.89 (0.77, 1.03) 0.95 (0.81, 1.11)
ACE 0.96 (0.83, 1.11) 0.91 (0.77, 1.07)
BB 1.00 (0.85, 1.19) 0.93 (0.77, 1.12)
*Patients were eligible for both California Medicaid and Medicare.
ACE, angiotensin-converting enzyme inhibitors; AH, antihypertensive medication; BB, beta-adrenergic blocker; CCB, calcium channel blockers, CI, conﬁdence interval; LL, lipid-lowering
medication.
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and that any differences in magnitude were less than 5%. The
conclusions from the logistic regression models remain the same.
We believe that the data with the larger sample size are more
representative of real world compliance with these two medica-
tion classes. Third, information on education level was unavail-
able in the data set. It has been well documented that patient
characteristics are associated with the use of AH drugs. Education
level may have an impact on knowledge of disease and health
beliefs, which may in turn be associated with medication adher-
ence. Further research in combining administrative claims data
and survey data focusing on social economics and perceived health
information is necessary to better understand medication adher-
ence behavior. Fourth, the factors that impact medication compli-
ance are complex. We were not able to include information on
the formulary structure, ﬁxed-dose medications, copayments, or
other drugs ormedical plan structures that may affect compliance.
Finally, because our study was conducted within a Medi-Cal
population, our data may be less generalizable to the general
population in the United States. Additional research in a more
diverse population is needed to complement our study ﬁndings.
Conclusions
Our ﬁndings in a Medi-Cal population indicate that the adher-
ence rates for both AH and LL were low in the ﬁrst year follow-
ing initial prescription, and continued to remain low through the
subsequent 5 years of the study period. Patients who were FA
with both drugs at baseline were more likely to maintain their
adherence status. Patients PA to one and FA to another medica-
tion were more likely to transition to full adherence in both
drugs. Nevertheless, those who were NA for one or both drugs at
Y1 had the highest probability of maintaining or transitioning to
nonadherence with both drugs. Race, insurance coverage, and
type of LL medication may have a signiﬁcant impact on transi-
tioning from a higher adherent to a lower adherent status. These
ﬁndings will be useful in guiding future cost-effectiveness analy-
ses incorporating adherence estimates.
Source of ﬁnancial support: Research funding for this study was provided
by Pﬁzer, Inc. as part of an unrestricted research grant.
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